Impact of Macular Perfusion During DME Management

In this interview from ASRS 2017, Dr. Charles Wykoff discusses findings from his study evaluating whether baseline macular perfusion status affected visual and anatomic outcomes during DME management. The study was a secondary analysis of the phase 3 VISTA study, where patients were randomized into one of two aflibercept arms (dosed every 4 weeks or 8 weeks) or to macular laser. While baseline macular nonperfusion was a marker of more advanced disease, it was not found to impact visual outcomes. Patients in the aflibercept group experienced greater visual and anatomic improvements than those in the laser group.

Relevant Financial Status: Dr. Wykoff is a consultant for, receives grant support and collects lecture fees from Regeneron.